ISO 14949:2001 PDF

Overview

ISO 14949:2001 - "Implants for surgery - Two-part addition-cure silicone elastomers" specifies the characteristics and test methods for two‑part, platinum‑catalyzed addition‑cure silicone elastomers (high consistency or liquid) intended for use in the manufacture, partially or totally, of surgical implants. The standard covers formulation, raw‑material assessment, biocompatibility expectations, physicomechanical characterization, purity and particulate limits, cure validation and required documentation.

Key topics and technical requirements

• Formulation ranges: Guidance on typical composition (silicone polymer 60–80% mass fraction; reinforcing agent <40%; crosslinker 1–5%; catalyst <0.5%; inhibitor <1.0%).
• Raw‑material assessment: Annual or every‑10th‑lot audits for polymer structure (e.g., NMR), silica purity (elemental analysis), treating agent and inhibitor structure/purity (e.g., IR), and crosslinker identity.
• Biocompatibility: Material biocompatibility must be demonstrated per ISO 10993‑1; testing repeated periodically (recommended every 5–10 years).
• Characterization & test slabs: Prepare 2 ± 0.2 mm test slabs (per ISO 34‑1) and perform identification (IR spectrum peaks defined in the standard) and cure‑rate assessment (referenced curemeter methods).
• Purity & contamination limits:
  • Metal impurities: Elemental limits specified per element (e.g., Al ≤ 200 × 10^-6; P, Ti, Fe ≤ 50 × 10^-6; Na, Mg, Ca ≤ 100 × 10^-6; many trace metals ≤ 10 × 10^-6 - all mass‑fraction limits).
  • Particulate contamination: Maximum allowable particle counts by size when viewed at 10× magnification (e.g., none >400 µm; defined maxima in ranges 399–300 µm, 299–200 µm, 199–100 µm).
  • Extractables/volatiles: Substances soluble in hexane ≤ 3% mass fraction; volatile matter ≤ 2.0% mass fraction (tests described in normative annexes).
• Cytotoxicity: Each production lot must pass cytotoxicity testing per ISO 10993‑5.
• Documentation: Data sheets and certificates of analysis are required for traceability and quality control.

Applications and users

• Intended for medical device manufacturers producing implantable parts (totally or partially made from addition‑cure silicone).
• Material suppliers and formulators use ISO 14949 to qualify product specifications, testing regimes and documentation.
• Quality, regulatory and R&D teams rely on the standard for material selection, process validation, biocompatibility strategy and supplier audits.
• Applicable to implantable product development, production control, supplier qualification and regulatory submissions.

Related standards

• ISO 10993‑1, ISO 10993‑5 (biological evaluation)
• ISO 34‑1 (test slab preparation), ISO 3417, ISO 6502 (cure measurements)
• ISO 48, ISO 527‑2 (mechanical characterization)

Keywords: ISO 14949:2001, two‑part addition‑cure silicone elastomers, implants for surgery, silicone elastomer, biocompatibility, purity testing, particulate contamination, cure rate, medical device materials.